Angiotensin II Receptor Blockers (ARBs) are the newest antihypertensive drugs. They modulate the rennin-angiotensin-aldosterone system by directly blocking the angiotensin II type 1 receptor site, thus blocking angiotensin II mediated vasoconstriction and aldosterone release.
Although losartan, the first drug of ARBs, was less potent than high doses of ACEIs in reducing blood pressure, the newer ARBs (such as valsartan, irbesartan, candesartan, telmisartan and eprosartan) appear to be equipotent to ACEIs. ARBs can improve cardiovascular outcomes in patients with HF and type 2 DM with nephropathy. Due to the absence of long-term data, ARBs are commonly recommended in the case of ACEIs intolerance[236].
Dostları ilə paylaş: |
